Please login to the form below
imetelstat
This page shows the latest imetelstat news and features for those working in and with pharma, biotech and healthcare.
Geron poleaxed as partner J&J abandons only pipeline drug
raising questions about imetelstat’s potential in particular and the emerging telomerase inhibitor class in general. ... Geron expects the transition of the complete imetelstat program to occur over approximately 12 months with operational support from
Latest news
-
J&J aiming for above-average growth thanks to stream of blockbusters
Also name-checked in the R&D update was imetelstat for myelofibrosis, which J&J is co-developing with Geron for a number of indications under a $934m deal agreed in
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest Intelligence
-
Deal Watch table for November 2014
Licence. 1, 051. Geron Corporation / J&J (Janssen). GRN163L, Imetelstat and tolerase inhibitor.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- BMS will not launch cancer drug Opdualag in Germany due to pricing pressures
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- LEO Pharma enters clinical trial partnership with ICON
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Roche’s Polivy backed by FDA Advisory Committee for lymphoma therapy
- How to create content for health professionals
- Sanofi to cut US insulin prices by up to 78% in January 2024
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- 2023 PM Society Awards – winners announced
- Next congress, please: making the most of virtual pharmaceutical congresses
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- A relentless commitment to neuroscience
- Trust me, I’m from pharma
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
PMHub
Thrive Agency
We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...
Latest intelligence
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- By offering patients knowledge, skills and confidence, they empower patients to be more actively involved in their health. Holistic support can help tackle adherence, mental health or anything else patients...
- THE EVOLVING ROLE OF PROCUREMENT?
- Procurement is evolving to reinforce its position as a strategic enabler of company growth. How can agency partners organisations to realise this?...
